Therapeutic Ex Vivo-expanded Allogeneic gamma delta T-cells TCB-202

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** An off-the-shelf preparation of a subset of therapeutic, ex vivo-expanded, allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic ex vivo-expanded allogeneic gamma delta T-cells TCB-202, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.

**Synonyms:** - Ex-vivo Expanded Allogeneic gd T-lymphocytes - OmnImmune - TCB 202 - TCB-202 - TCB-202 - TCB202 - Therapeutic Ex Vivo-expanded Allogeneic gamma, delta T-Cells